Use of Rituximab Biosimilar With CHOP to Treat DLBCL Is Effective, EHA Abstracts Find - AJMC.com Managed Markets Network
6/10/2022 12:00:00 AM2 years 10 months ago
by Laura Joszt, MA
by Laura Joszt, MA
Using biosimilar rituximab to replace the reference in a common combination regimen to treat diffuse large B-cell lymphoma (DLBCL) results in similar outcomes.
The combination regimen rituximab (Rituxan), cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), and prednisone (R-CHOP) is a common treatment for diffuse large B-cell lympho… [+3889 chars]
full article...